{"id":390048,"date":"2021-04-06T00:00:00","date_gmt":"2021-04-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2020-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2020\/"},"modified":"2026-04-22T05:22:14","modified_gmt":"2026-04-22T05:22:14","slug":"dlsfhe0001-2020-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2020-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2020\/","title":{"rendered":"Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2020"},"content":{"rendered":"<p>DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With the emergence of Roche \/ Chugai\u2019s bispecific antibody Hemlibra and a diverse pipeline, both in terms of technology type and administration route, we forecast a significant change in approach to disease management for many patients. The R&#038;D emphasis has shifted to nonfactor treatment approaches to restore coagulation. Examples include Sanofi\u2019s anti-ATIII siRNA fitusiran, Novo Nordisk\u2019s anti-TFPI MAb concizumab, and BioMarin\u2019s gene therapy BMN 270. Despite novel nonfactor hemophilia agents forecast to launch, we expect the demand for factor-based concentrates to persist.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How will physicians treating hemophilia A differentiate between the emerging therapies? Which therapies will gain the greatest market share in an increasingly stringent regulatory environment?<\/li>\n<li>What clinical roles will Roche \/ Chugai\u2019s Hemlibra, Sanofi\u2019s fitusiran, Novo Nordisk\u2019s concizumab, and gene therapy play in the evolving hemophilia A treatment landscape?<\/li>\n<li>How will the management of patients with inhibitors change when new treatment options become available? How will Hemlibra\u2019s head start on its novel competitors play out over the forecast period?<\/li>\n<li>How will the factor VIII concentrate market evolve? How will nonfactor treatment options impact the multitude of brands vying for patient share in this space?<\/li>\n<li>What do interviewed payers advise developers to do to drive market access of new hemophilia drugs? To what extent will the cost of FVIII gene therapy drive its rationing in terms of a patient\u2019s capacity to derive benefit?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390048","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hemophilia","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390048\/revisions"}],"predecessor-version":[{"id":576417,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390048\/revisions\/576417"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}